We are pleased to announce that we are expanding the international coverage of our products thanks to the recent signature of agreements with both new and loyal partners. These new partnerships further enable us to spread our global footprint. Soon you will be able to find our products in the [...]
Barcelona, Spain, February 22, 2018 – Noventure and Laboratorios Salvat, S.A. (Salvat), announce today that they have entered into an agreement in which Salvat will distribute Noventure’s nasal mucoprotection product in Spain and Portugal. The product contains a mucomimetic agent that forms a protective barrier over the nasal epithelial mucosa. This [...]
We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is commercialized over the French territory under the umbrella brand Cysticare / Utipro plus and is distributed by Vemedia, our partner for the product in the Netherlands as well. [...]
We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot. Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as [...]
We are pleased to announce the launch of Tasectan® Duo in Austria by our partner company Montavit. This will be Duo´s second market, after the successful introduction in Italy by Angelini. Tasectan® Duo is the first combination of gelatin tannate and inactivated bacteria, and can be used to re-establish [...]
New partnership: Xilaplus® AF in Turkey Noventure is delighted to announce its new partnership with Generica İlaç to market Noventure’s Xilaplus® AF in Turkey. Xilaplus® AF is a Class IIa CE marked medical device specifically formulated for the control and reduction of diarrheal events of various etiologies. Xilaplus® AF acts [...]
European Association of Urology – London 25th – 27th March 2017. More than 10.300 total participants, coming from 113 countries all over the world. Out of around 10.000 delegates, mainly urologists, nearly 20% were residents. 200 exhibitors took part to the congress, thus adding further 2200 participants to the event. [...]
Barcelona, March 13, 2017 – Noventure and Riksförbundet för sexuell upplysning (RFSU), the Swedish Association for Sexuality Education, announce today that they have entered into an agreement by which RFSU will distribute Noventure’s Utipro® Plus in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). With this agreement, Utipro Plus [...]
In order to further disseminate its proprietary barrier technology, on which the new concept “mucoprotection” is based, and as part of its continuous investment in its products´ reputation, Noventure has just participated in this year´s ESPGHAN Congress, held in Prague. Pediatric gastroenterologists are a key target group for the recommendation [...]
L. Lopetuso, C. Graziani, A. Guarino, A. Lamborghini, S. Masi, V. Stanghellini Eur Rev Med Pharmacol Sci . 2017; 21 (4): 873-883 Researchers from the A. Gemelli Foundation, School of Medicine, Rome, Italy have published an extensive review on the role of Gelatin tannate and tyndallized probiotics (Tasectan Duo) in [...]